

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Keymed Biosciences Inc.
康諾亞生物醫藥科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2162)

VOLUNTARY ANNOUNCEMENT

INCREASE IN SHAREHOLDING BY THE CONTROLLING SHAREHOLDER

This announcement is made by Keymed Biosciences Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company is pleased to announce that on November 30, 2021, Dr. Bo CHEN (the executive Director, chairman of the Board of Directors and a controlling shareholder of the Company) acquired 65,000 additional shares of the Company (the “**Shares**”) from the market through an entity under his control, Moonshot Holdings Limited (“**Moonshot**”) at a total consideration of HK\$3.06 million (translating into an average price of approximately HK\$47.05 per Share) (the “**Shareholding Increase**”).

As informed by Dr. Bo CHEN, the Shareholding Increase was made as he and other controlling shareholders of the Company are highly confident towards the research and development of the Company’s pipeline product, as well as the overall prospect and growth potential of the Company and do not rule out any further acquisition of the Shares as and when appropriate in accordance with the laws and regulations.

Moonshot is a member of the group of controlling shareholders of the Company. Dr. Bo CHEN holds 65.36% equity interest in Moonshot. Immediately after the Shareholding Increase, Moonshot directly holds and Dr. Bo CHEN is regarded as interested in 77,877,482 Shares and 95,853,635 Shares, representing approximately 27.84% and 34.27% of the total share capital of the Company as at the date of this announcement, respectively.

According to the information available to the Company and so far as the Directors are aware, the Company has maintained sufficient public float of the Shares in issue upon completion of the Shareholding Increase and as at the date of this announcement.

By order of the Board of Directors
Keymed Biosciences Inc.
Dr. Bo CHEN
Chairman

Hong Kong, November 30, 2021

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Bo CHEN, Dr. Changyu WANG and Dr. Gang XU as executive Directors; Mr. Qi CHEN, Dr. Dong LYU, Dr. Min Chuan WANG and Mr. Yilun LIU as non-executive Directors; Prof. Xiao-Fan WANG, Prof. Yang KE, Mr. Cheuk Kin Stephen LAW and Prof. Linqing LIU as independent non-executive Directors.